
    
      OBJECTIVES: I. Assess the response of patients with adrenocortical carcinoma treated with
      suramin. II. Evaluate the qualitative and quantitative toxic effects of this therapy.

      OUTLINE: Patients are described according to stage, performance status, prior radiotherapy,
      prior surgery, and prior mitotane therapy. Patients receive suramin IV for 5 days in the
      first week, then twice a week for 2 weeks, and then weekly for a total of 12 weeks.
      Hydrocortisone is taken PO twice daily. Following a 12 week rest, patients receive a second
      course; those with stable or responding disease continue treatment for a maximum of four
      courses.

      PROJECTED ACCRUAL: A maximum of 40 patients will be accrued at a rate of 6-7 per year.
    
  